There is no doubt that with the help of sequential therapy of multiple generations of TKIs and local treatment, patients diagnosed with EGFR/ALK-positive NSCLC with BM can live significantly longer than before. This evidence concerns the gene EGFR and non-small cell lung carcinoma.